Thus, the proportion of CD20+ B lymphocytes and the CD8-to-CD20 lymphocytes ratio in the stroma of endometrial cancer serves as both a predictive marker of response to immunotargeted therapy and a prognostic factor for progression-free survival in patients. This evidence concerns the gene CD8A and endometrial cancer.